Skip to content

Trial Using Impella LP 2.5 System in Patients With Acute Myocardial Infarction Induced Hemodynamic Instability

RECOVER II Trial: A Prospective Randomized Trial Investigating the Use of the IMPELLA RECOVER LP 2.5 System in Patients With Acute Myocardial Infarction Induced Hemodynamic Instability

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00972270
Acronym
RECOVER II
Enrollment
1
Registered
2009-09-04
Start date
2008-07-31
Completion date
2010-09-30
Last updated
2011-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction

Keywords

Arterial Occlusive Disease, Heart Diseases, Myocardial Ischemia, Vascular Disease, Arteriosclerosis, Ischemia

Brief summary

This is a randomized trial investigating the use of the IMPELLA RECOVER LP 2.5 compared to Intra-aortic balloon pump (IABP) in patients with Acute Myocardial Infarction.

Interventions

DEVICEImpella LP 2.5

Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5L/min.

The Intra-Aortic Balloon Pump consists of a cylindrical balloon that sits in the aorta and counterpulsates.

Sponsors

Abiomed Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Informed Consent * Subject presenting with STEMI undergoing primary PCI * Patient presents with at least 1 of the following: * Unstable blood pressure * Tachycardia and tissue hypoperfusion * The need for intravenous pressor or inotropic support * Patient presents with STEMI: * CK-MB\>2x normal

Exclusion criteria

* Unwitnessed cardiac arrest * Abnormalities of the aorta * Recent stroke or TIA * Mural thrombus in the left ventricle

Design outcomes

Primary

MeasureTime frameDescription
Composite rate of major adverse events within 30 days or hospital discharge.30 days or dischargeComposite rate of major adverse events within 30 days or hospital discharge.

Secondary

MeasureTime frameDescription
Maximum CPO increase from baseline.TreatmentMaximum CPO increase from baseline.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026